This trial is active, not recruiting.

Condition hypertension
Treatment lisinopril, atenolol
Sponsor Brigham and Women's Hospital
Collaborator University of Utah
Start date January 2007
End date March 2017
Trial size 100 participants
Trial identifier NCT01009944, 2007p002290


The purpose of this study is to develop an approach to provide personalized medicine to individuals who have hypertension (high blood pressure). The investigators plan to use people's genetic characteristics (traits) to determine what medication they should use to lower their blood pressure most effectively. The investigators will give individuals one of two medications to treat hypertension (lisinopril or atenolol). The investigators believe that depending on the individuals genetic background one medication will work better in lowering their blood pressure.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Intervention model single group assignment
Masking open label
Primary purpose treatment
lisinopril, atenolol Tenormin (Atenolol)
once a day for 14 weeks

Primary Outcomes

One type of blood pressure medication will better treat individuals with certain genetic backgrounds.
time frame: 16 weeks

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria: - Male and female hypertensive participants who were previously studied in SCOR program. Exclusion Criteria: - Diabetes - Taking other medications beside thyroid or estrogen supplements.

Additional Information

Official title Genetic Mechanisms in Human Hypertension RAAS Inhibition Study
Principal investigator Gordon H. Williams, MD
Trial information was received from ClinicalTrials.gov and was last updated in February 2016.
Information provided to ClinicalTrials.gov by Brigham and Women's Hospital.